Gen1e Lifesciences Inc.
USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Gen1e ranks #31,752 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 5 technology areas.
- #31,752
- of 49,997 US assignees by volume
- Top 13%
- by Innovation Score (50.5/100)
- 25.5
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R31752 · US Corporation #31,752 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 8 grants
- MID-PACK #31,752/49,997
- PHOTO-FINISH GE Aviation Czech S…
- CPC-NARROW A61P · 5 areas
- INNOV-PAR 50.5/100
- CLAIMS-DENSE 25.5 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2022–2025 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: GE Aviation Czech S.R.O. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Gen1e’s 50.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Gen1e
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Diehl Aerospace · near
Diehl Aerospace · near
51 score
- Face International… · near
Face International… · near
51 score
- Gen1e Lifesciences · this assignee
Gen1e Lifesciences · this assignee
51 score
- INV Nylon Chemicals… · near
INV Nylon Chemicals… · near
51 score
- Tata Steel · near
Tata Steel · near
51 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Gen1e's Innovation Score is 50.5/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Gen1e?
Each dot is one of Gen1e’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gen1e’s own 25.5 claims/patent is ABOVE the 9.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Gen1e's grants concentrate
Gen1e Lifesciences Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2023. By volume, Gen1e sits between GE Aviation Czech S.R.O. and Genereach Biotechnology Corporation.
Gen1e's three-year grant acceleration
Gen1e Lifesciences Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Gen1e's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- GE Aviation Czech…
GE Aviation Czech S.R.O.
8 patents
- GE Intellectual P…
GE Intellectual Property Licensing, LLC
8 patents
- GEA Westfalia Sep…
GEA Westfalia Separator Group GmbH
8 patents
- GEE HOO Fitec
GEE HOO Fitec Corp.
8 patents
- Gene Stream PTY
Gene Stream PTY Ltd.
8 patents
- General Plasma
General Plasma Inc.
8 patents
- General Printing…
General Printing & Design, Inc.
8 patents
- Genereach Biotech…
Genereach Biotechnology Corporation
8 patents
- Gen1e Lifesciences ◀
Gen1e Lifesciences Inc.
8 patents
What this shows Gen1e holds 8 patents at rank #31,738, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Gen1e
By rank, the assignees closest to #31,738 in granted patent volume.
- GE Aviation Czech S.R.O. #31,734 · 8 patents
- GE Intellectual Property Licensing, LLC #31,735 · 8 patents
- GEA Westfalia Separator Group GmbH #31,736 · 8 patents
- GEE HOO Fitec Corp. #31,737 · 8 patents
- Gene Stream PTY Ltd. #31,739 · 8 patents
- General Plasma Inc. #31,740 · 8 patents
- General Printing & Design, Inc. #31,741 · 8 patents
- Genereach Biotechnology Corporation #31,742 · 8 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Gen1e's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Gen1e, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Gen1e ranks #2,286 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (51 here).
Gen1e's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
51 Top 13% higher than 87% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 37.5% |
| 2023 | 1 | 12.5% |
| 2024 | 2 | 25.0% |
| 2025partial year | 2 | 25.0% |
Which technologies does Gen1e Lifesciences Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Gen1e Lifesciences Inc.'s patent record in context - here's where to go next.
- Gen1e Lifesciences Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #31,752 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Gen1e Lifesciences Inc. against GE Aviation Czech S.R.O., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 50.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.